Search

Displaying results 9401 - 9410 of 10000 in total
  1. Drug

    BMS-919373

    go.drugbank.com/drugs/DB15047
    Investigational

    BMS-919373 is under investigation in clinical trial NCT02153437 (Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers).

  2. Drug

    PD-0299685

    go.drugbank.com/drugs/DB15264
    Investigational

    PD-0299685 is under investigation in clinical trial NCT00314964 (Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause).

  3. Drug

    Temanogrel

    go.drugbank.com/drugs/DB05227
    Investigational

    APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena. … APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constriction and intimal hyperplasia mediated by serotonin.

  4. Drug

    RGX-501

    go.drugbank.com/drugs/DB17639
    Investigational

    It is being investigated for the treatment of homozygous familial hypercholesterolemia.[L46696] … RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of the human low-density lipoprotein receptor (LDLR) gene to liver cells.

  5. Drug

    Dabocemagene autoficel

    go.drugbank.com/drugs/DB17878
    Investigational

    Dabocemagene autoficel is an _ex vivo_, autologous cell-based gene therapy. It comprises autologous dermal fibroblasts genetically modified to express functional type VII collagen. … Developed by Castle Creek Biosciences Inc., dabocemagene autoficel is being investigated for the treatment of dystrophic epidermolysis bullosa.[L46797]

  6. Drug

    Saruparib

    go.drugbank.com/drugs/DB18982
    Investigational

    Saruparib is under investigation in clinical trial NCT06380751 (Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative

    Synonyms: 5-{4-[(7-ethyl-5,6-dihydro-6-oxo-1,5-naphthyridin-3- yl)methyl]piperazin-1-yl}-N-methylpyridine-2- carboxamide, 2-Pyridinecarboxamide, 5-[4-[(7-ethyl-5,6-dihydro-6-oxo-1,5-naphthyridin-3-yl)methyl]-1-piperazinyl]-N-methyl-
  7. Drug

    Zanidatamab zovodotin

    go.drugbank.com/drugs/DB15472
    Experimental

    According to Zymeworks, "ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on the same antibody framework as [ZW25] but armed with a cytotoxic payload." … [L8234] It is being investigated for several indications characterized by HER2 expression including breast and gastric cancers that have progressed or are refractory to existing HER2-targeted therapies

  8. Drug

    GSK2245035

    go.drugbank.com/drugs/DB16076
    Investigational

    GSK2245035 is under investigation in clinical trial NCT02833974 (Effect of the GSK2245035 on the Allergen-induced Asthmatic Response).

  9. Drug

    Stapokibart

    go.drugbank.com/drugs/DB18990
    Investigational

    Stapokibart is under investigation in clinical trial NCT06424470 (Study on the Treatment of Prurigo Nodularis With Stapokibart Injection).

  10. Drug

    Supinoxin

    go.drugbank.com/drugs/DB19010
    Investigational

    Supinoxin is under investigation in clinical trial NCT02003092 (RX-5902 Treatment of Subjects With Triple Negative Breast Cancer).

    Synonyms: 1-(3,5-dimethoxyphenyl)-4-((6-fluoro-2-methoxyquinoxalin-3-yl)aminocarbonyl) piperazine, 4-(3,5-dimethoxyphenyl)-n-(7-fluoro-3-methoxy-quinoxalin-2-yl)piperazine-1-carboxamide